Trastuzumab Does Not Directly Cause Peripheral Neuropathy
Trastuzumab (Herceptin) monotherapy is not associated with peripheral neuropathy as a direct adverse effect. However, peripheral neuropathy frequently occurs when trastuzumab is combined with neurotoxic chemotherapy agents, particularly taxanes (paclitaxel, docetaxel), which are the actual culprits causing nerve damage.
Evidence from FDA Drug Labeling
The official FDA prescribing information for Herceptin lists peripheral neuropathy-related adverse events, but critically, these occurred predominantly in combination therapy settings 1:
In the HERA trial (trastuzumab monotherapy): Paresthesia occurred in only 2% vs 0.6% in observation arm—a minimal difference suggesting no significant neuropathy risk from trastuzumab alone 1
In NCCTG N9831 (trastuzumab + taxane chemotherapy): Motor and sensory neuropathy were specifically tracked as "toxicities associated with taxanes," with Grade 2-5 neuropathy rates higher in the combination arm 1
In metastatic breast cancer studies: When trastuzumab was combined with paclitaxel, peripheral neuritis (2% vs 2%) and neuropathy (1% vs 4%) occurred, but rates were similar or lower in the trastuzumab combination arm compared to chemotherapy alone 1
Key Clinical Distinction
The peripheral neuropathy observed in trastuzumab-treated patients is chemotherapy-induced peripheral neuropathy (CIPN), not trastuzumab-induced neuropathy 2. The ASCO guideline on CIPN management specifically identifies taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib as causative agents—trastuzumab is notably absent from this list 2.
Real-World Evidence
Recent studies confirm this distinction:
A 2025 real-world cohort of 102 patients receiving adjuvant trastuzumab emtansine (T-DM1, which contains a microtubule inhibitor payload) showed peripheral neuropathy requiring dose reduction in 14 patients and treatment discontinuation in 10 patients 3—but this was due to the DM1 cytotoxic component, not the trastuzumab antibody
A 2021 meta-analysis demonstrated that T-DM1 actually had lower risk of peripheral neuropathy compared to taxane-based regimens (RR 0.59 for all-grade PN, p=0.01) 4, further supporting that trastuzumab itself is not neurotoxic
In a 2026 study of neoadjuvant TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab), 21.4% developed CIPN requiring treatment modification 5—this was clearly taxane-induced, as switching to anthracyclines (non-neurotoxic) after docetaxel discontinuation still achieved high response rates
Important Clinical Caveats
When peripheral neuropathy occurs in patients receiving trastuzumab:
Identify the true culprit: Review all concurrent medications—taxanes are the most common cause in HER2-positive breast cancer regimens
Manage according to CIPN guidelines: Consider dose reduction, delay, or discontinuation of the neurotoxic chemotherapy agent (not trastuzumab) 2
Duloxetine is the only evidence-based treatment for established painful CIPN, though benefit is limited 2
Trastuzumab can typically be continued when neuropathy develops, as it is not the causative agent—the chemotherapy component should be modified instead 5
Rare exception: One case report described central neurotoxicity (blurred vision, diplopia) with T-DM1 6, and intrathecal trastuzumab caused peripheral neuropathy in 1 patient 7—but these are extremely uncommon scenarios not relevant to standard intravenous trastuzumab use
The bottom line: Attribute peripheral neuropathy to the chemotherapy backbone (especially taxanes), not to trastuzumab itself, and adjust treatment decisions accordingly.